Clinical characteristics and drug susceptibility patterns of Corynebacterium species in bacteremic patients with hematological disorders
Authors:
- 24 April 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (10) , 2095-2104
Abstract
The aim of this study was to clarify the clinical and microbiological characteristics of Corynebacterium bacteremia in hematological patients. We retrospectively reviewed the medical records of patients with Corynebacterium bacteremia from April 2013 to June 2018. The causative Corynebacterium species were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Drug susceptibility tests were performed using the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. In total, 147 cases of Corynebacterium bacteremia were identified during the study period. Corynebacterium striatum was the most frequent pathogen. Catheter-related bloodstream infection was diagnosed in 19.7% of all patients, and moderate/severe oral or severe gastrointestinal mucosal impairment was detected in 19.7%. Polymicrobial infection was found in about 20% of cases, with Enterococcus faecium being the most frequent isolate. The overall 30-day mortality was 34.7% (51/147). Multivariate analysis showed that E. faecium co-infection (odds ratio (OR) 9.3; 95% confidence interval (CI) 2.1–40), systemic corticosteroids (OR 3.6; 95% CI 1.4–8.9), other immunosuppressive drugs (OR 0.32; 95% CI 0.13–0.76), and a Pitt bacteremia score ≥4 (OR 12; 95% CI 3.9–40) were significant risk factors for overall 30-day mortality. The drug susceptibility rates for beta-lactam antimicrobial agents were quite low. All isolates were susceptible to glycopeptides and linezolid. However, some C. striatum isolates were resistant to daptomycin. Corynebacterium bacteremia can occur in the presence of several types of mucosal impairment. Our drug susceptibility data indicate that Corynebacterium bacteremia in hematological patients could be treated by glycopeptides or linezolid.Keywords
This publication has 36 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Microbiological investigation and clinical significance of Corynebacterium spp. in respiratory specimensDiagnostic Microbiology and Infectious Disease, 2012
- Enterococcal Bacteremia Is Associated With Increased Risk of Mortality in Recipients of Allogeneic Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2012
- Bloodstream Infection Caused by Nontoxigenic Corynebacterium diphtheriae in an Immunocompromised Host in the United StatesJournal of Clinical Microbiology, 2012
- The Clinical and Prognostic Importance of Positive Blood Cultures in AdultsThe American Journal of Medicine, 2010
- Catheter-related Corynebacterium bacteremia: should the catheter be removed and vancomycin administered?European Journal of Clinical Microbiology & Infectious Diseases, 2009
- In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteriaInternational Journal of Antimicrobial Agents, 2007
- Emergence of multidrug-resistant Corynebacterium striatum as a nosocomial pathogen in long-term hospitalized patients with underlying diseasesDiagnostic Microbiology and Infectious Disease, 2006
- Corynebacterium resistens sp. nov., a New Multidrug-Resistant Coryneform Bacterium Isolated from Human InfectionsJournal of Clinical Microbiology, 2005
- Infection Due to Corynebacterium Species in Marrow Transplant PatientsAnnals of Internal Medicine, 1979